Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 830 across all filing types
Latest filing 2022-02-03 Director's Dealing
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2022-02-03 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to the issuance of shares upon exercise of warrants. It includes detailed descriptions of the securities, risk factors, use of proceeds, and other offering details. It is part of a registration statement and references SEC filings such as Form S-1 and Form S-3. This type of document is a capital raising and financing disclosure, not a financial report, management discussion, or other report types. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, consistent with a prospectus for securities issuance.
2022-02-02 English
Regulatory Filings 2022
Regulatory Filings
2022-02-02 English
POS EX
Regulatory Filings Classification · 100% confidence The document is a Post-Effective Amendment No. 3 to a Form S-1 registration statement filed on Form S-3 with the SEC. It is related to securities registration under the Securities Act of 1933 and includes exhibits such as legal opinions and consents. The document does not contain financial statements or earnings data but is a regulatory filing related to securities registration and amendments. It is not an earnings release, annual report, or other financial report but a regulatory filing updating the registration statement. Therefore, it fits best under Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a full financial report but a detailed regulatory amendment filing.
2022-01-28 English
POS AM
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 2 to a Form S-1 registration statement, converted to a Form S-3 registration statement, filed with the SEC. It relates to the registration of securities for sale, specifically common stock issuable upon exercise of warrants. The document is a detailed SEC filing concerning capital raising and securities registration, not a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive registration details and legal disclosures. The document fits the category of Capital/Financing Update, as it updates on the company's securities registration and capital structure changes related to warrants and stock issuance.
2022-01-25 English
FORM 424B3
Capital/Financing Update Classification · 95% confidence The document is a Form 424B3 prospectus supplement filed pursuant to SEC rules, which updates a prior prospectus related to an offering of common stock and warrants. It incorporates by reference a Current Report on Form 8-K filed on January 19, 2022. The Form 8-K includes a press release and a letter to shareholders detailing the company's strategic focus, clinical development strategy, and preliminary cash balance, as well as announcing a conference call and webcast with a slide presentation. The content focuses on capital raising activities, including share offerings and warrants, and financial updates related to the company's cash position and strategic plans. There is no detailed financial statement or comprehensive financial report such as an annual or quarterly report. Instead, the document primarily serves as a capital/financing update and related investor communication. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-01-20 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.